We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Maximus (MMS) Stock to Your Portfolio Now
Read MoreHide Full Article
Maximus, Inc. (MMS - Free Report) shares have returned 4.3% in the past three months and we believe that the stock has the potential to sustain its momentum in the near term.
The company carries a Zacks Rank #2 (Buy) at present. Our research shows that stocks with a Zacks Rank #1 (Strong Buy) or 2, offer attractive investment opportunities. Thus, MMS is a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for fiscal 2024 earnings is pegged at $5.41, reflecting 41.3% year-over-year growth. Earnings are expected to register 5.7% growth in fiscal 2025. Over the past 60 days, the consensus estimate has moved 0.6% north.
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise and its ability to deliver cost-effective, efficient and high-scale solutions position it as a lucrative partner to governments.
Maximus maintains solid relationships and a strong reputation with governments. Its long-term contracts provide the company with predictable recurring revenue streams. It continuously seeks long-term relationships with clients in not only those markets where they operate but also in adjacent ones.
MMS is also focused on expanding its foothold in clinical services, as well as in long-term services and supports. Moreover, complex health needs have increased the requirement for government social benefits and safety-net programs. This is expected to continue driving demand for the company’s services.
MMS has a solid track record of dividend payments. During fiscal 2023, 2022 and 2021, Maximus paid cash dividends of $68 million, $68.7 million and $68.8 million, respectively. Such moves indicate Maximus’ commitment to create value for shareholders and underline its confidence in its business.
APi Group currently sports a Zacks Rank of 1. It has a long-term earnings growth expectation of 17.9%. APG delivered a trailing four-quarter earnings surprise of 5.1%, on average.
Cellebrite DI Ltd. currently carries a Zacks Rank of 2. It has a long-term earnings growth expectation of 18%. CLBT delivered a trailing four-quarter earnings surprise of 237.5%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Reasons to Add Maximus (MMS) Stock to Your Portfolio Now
Maximus, Inc. (MMS - Free Report) shares have returned 4.3% in the past three months and we believe that the stock has the potential to sustain its momentum in the near term.
The company carries a Zacks Rank #2 (Buy) at present. Our research shows that stocks with a Zacks Rank #1 (Strong Buy) or 2, offer attractive investment opportunities. Thus, MMS is a compelling investment proposition at the moment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Maximus, Inc. Price
Maximus, Inc. price | Maximus, Inc. Quote
The Zacks Consensus Estimate for fiscal 2024 earnings is pegged at $5.41, reflecting 41.3% year-over-year growth. Earnings are expected to register 5.7% growth in fiscal 2025. Over the past 60 days, the consensus estimate has moved 0.6% north.
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise and its ability to deliver cost-effective, efficient and high-scale solutions position it as a lucrative partner to governments.
Maximus maintains solid relationships and a strong reputation with governments. Its long-term contracts provide the company with predictable recurring revenue streams. It continuously seeks long-term relationships with clients in not only those markets where they operate but also in adjacent ones.
MMS is also focused on expanding its foothold in clinical services, as well as in long-term services and supports. Moreover, complex health needs have increased the requirement for government social benefits and safety-net programs. This is expected to continue driving demand for the company’s services.
MMS has a solid track record of dividend payments. During fiscal 2023, 2022 and 2021, Maximus paid cash dividends of $68 million, $68.7 million and $68.8 million, respectively. Such moves indicate Maximus’ commitment to create value for shareholders and underline its confidence in its business.
Other Stocks to Consider
A couple of other top-ranked stocks from the broader Zacks Business Services sector are APi Group (APG - Free Report) and Cellebrite DI Ltd. (CLBT - Free Report) .
APi Group currently sports a Zacks Rank of 1. It has a long-term earnings growth expectation of 17.9%. APG delivered a trailing four-quarter earnings surprise of 5.1%, on average.
Cellebrite DI Ltd. currently carries a Zacks Rank of 2. It has a long-term earnings growth expectation of 18%. CLBT delivered a trailing four-quarter earnings surprise of 237.5%, on average.